HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

G Castaman Selected Research

von Willebrand Diseases (von Willebrand's Disease)

1/2019Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.
4/2015No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance.
5/2014Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.
1/2013Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
5/2012Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation.
4/2012Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients.
12/2010Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies.
9/2010Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.
9/2010Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype.
9/2010Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


G Castaman Research Topics

Disease

28Hemorrhage
01/2019 - 03/2000
22von Willebrand Diseases (von Willebrand's Disease)
01/2019 - 01/2000
12Hemophilia A (Haemophilia)
10/2020 - 10/2001
9Type 1 von Willebrand Disease
09/2010 - 03/2000
4Thrombosis (Thrombus)
06/2018 - 06/2000
3Venous Thrombosis (Deep-Vein Thrombosis)
01/2007 - 06/2000
3Venous Thromboembolism
12/2000 - 06/2000
2Hemophilia B (Haemophilia B)
10/2020 - 01/2012
2Hypersensitivity (Allergy)
01/2019 - 09/2013
2Afibrinogenemia (Fibrinogen Deficiency)
12/2009 - 05/2008
2Type 3 von Willebrand Disease
01/2009 - 02/2004
2Protein S Deficiency (Deficiency, Protein S)
01/2007 - 06/2000
2Type 2 von Willebrand Disease
02/2006 - 01/2000
2Activated Protein C Resistance (APC Resistance)
09/2001 - 08/2000
1Immune System Diseases (Immune Disorders)
03/2017
1Neoplasms (Cancer)
03/2017
1Nephrotic Syndrome (Syndrome, Nephrotic)
09/2013
1Body Weight (Weight, Body)
12/2009
1Infarction (Infarctions)
03/2009
1Virus Diseases (Viral Diseases)
01/2008
1Hemostatic Disorders
07/2007
1Bites and Stings (Sting)
05/2007
1Epistaxis (Nosebleed)
05/2007
1Atherosclerosis
02/2004
1Infections
10/2001
1Factor XIII Deficiency
06/2001
1Disease Susceptibility (Diathesis)
06/2001
1Thrombophilia
12/2000

Drug/Important Bio-Agent (IBA)

32von Willebrand FactorIBA
01/2019 - 01/2000
11Factor VIII (Coagulation Factor VIII)IBA
03/2017 - 10/2001
7Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric
08/2011 - 09/2002
5AntigensIBA
04/2015 - 05/2007
4Factor V (Coagulation Factor V)IBA
01/2011 - 06/2000
4Biomarkers (Surrogate Marker)IBA
09/2010 - 04/2006
4factor V LeidenIBA
12/2000 - 06/2000
3Prothrombin (Factor II)IBA
09/2001 - 06/2000
26-pyruvoyltetrahydropterin synthase (PTPS)IBA
10/2020 - 03/2017
2Factor IX (Coagulation Factor IX)FDA LinkGeneric
10/2020 - 10/2001
2AntibodiesIBA
01/2019 - 07/2007
2Messenger RNA (mRNA)IBA
08/2011 - 09/2010
2Biological ProductsIBA
08/2011 - 11/2009
2Hemostatics (Antihemorrhagics)IBA
06/2011 - 07/2007
2Protein SIBA
01/2007 - 06/2000
2Cysteine (L-Cysteine)FDA Link
05/2006 - 02/2004
2Protein CIBA
09/2001 - 11/2000
1factor VIII-Fc fusion proteinIBA
01/2017
1von Willebrand factor drug combination factor VIIIIBA
04/2015
1Factor XI (Plasma Thromboplastin Antecedent)IBA
01/2014
1Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
06/2013
1antineoplaston A10 (A 10)IBA
01/2012
1Factor VII (Proconvertin)IBA
01/2012
1Rituximab (Mabthera)FDA Link
09/2011
1recombinant FVIIa (rFVIIa)FDA Link
01/2011
1LatexIBA
09/2010
1Blood Group Antigens (Blood Groups)IBA
09/2010
1Fibrinogen (Factor I)FDA Link
12/2009
1Progestins (Progestagens)IBA
03/2009
1BBeta fibrinogenIBA
05/2008
1Factor XIII (Coagulation Factor XIII)IBA
01/2008
1CoagulantsIBA
01/2008
1Vasopressins (Vasopressin)IBA
01/2008
1Blood Coagulation Factors (Coagulation Factor)IBA
07/2007
1Nonsense Codon (Nonsense Mutation)IBA
05/2007
1Blood Proteins (Serum Proteins)IBA
01/2007
1Tranexamic Acid (AMCA)FDA Link
10/2006
1Phenylalanine (L-Phenylalanine)FDA Link
05/2006
1AlbuminsIBA
10/2001
1NucleotidesIBA
06/2001
1AnticoagulantsIBA
12/2000
1Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
03/2000

Therapy/Procedure

4Therapeutics
09/2013 - 12/2005
2Blood Transfusion (Blood Transfusions)
10/2006 - 12/2005
1Surgical Amputation (Amputations)
03/2009
1Tooth Extraction (Tooth Extractions)
04/2006
1Cesarean Section (Caesarean Section)
02/2006
1Aftercare (After-Treatment)
10/2001